Zobrazeno 1 - 10
of 92
pro vyhledávání: '"Robert J Sanchez"'
Autor:
Dana J Murdock, Keran Moll, Robert J Sanchez, Jing Gu, Sergio Fazio, Gregory P Geba, Fatima Rodriguez
Publikováno v:
American Journal of Preventive Cardiology, Vol 19, Iss , Pp 100721- (2024)
Objective: Apolipoprotein B (ApoB) and lipoprotein (a) (Lp[a]) are predictors of cardiovascular disease (CVD) risk; therefore, current recommendations for CVD risk assessment and management advocate that patients receive testing for ApoB and Lp(a) in
Externí odkaz:
https://doaj.org/article/fa900fa251a849c399097008524362dd
Autor:
Mohamed Hussein, Degang Wang, David M Weinreich, Robert J Sanchez, Wenhui Wei, Boaz Hirshberg, Vera Mastey, Jessica J Jalbert, Dana J Murdock
Publikováno v:
BMJ Open, Vol 12, Iss 12 (2022)
Objective To assess the real-world effectiveness of casirivimab and imdevimab (CAS+IMD) versus no COVID-19 antibody treatment among patients diagnosed with COVID-19 in the ambulatory setting, including patients diagnosed during the Delta-dominant per
Externí odkaz:
https://doaj.org/article/bc1da9cd24d248a385655ccb910d2dc7
Publikováno v:
American Journal of Preventive Cardiology, Vol 10, Iss , Pp 100336- (2022)
Objective: To update the prevalence of atherosclerotic cardiovascular disease (ASCVD) in the United States (US) and re-evaluate lipid-lowering therapies (LLT) utilization and low-density lipoprotein cholesterol (LDL-C) goal attainment among ASCVD pat
Externí odkaz:
https://doaj.org/article/642ba85582cf4731ba22248d0bae18e1
Publikováno v:
Journal of Clinical Lipidology. 16:901-905
We aim to estimate the number and proportion of very-high risk patients with atherosclerotic cardiovascular disease (ASCVD) who would be able to achieve low-density lipoprotein cholesterol (LDL-C)70 mg/dL with various lipid-lowering therapies (LLTs),
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f4d026699d277e3c7275841ddf6d2b
https://doi.org/10.1016/j.jacl.2022.10.001
https://doi.org/10.1016/j.jacl.2022.10.001
Autor:
Jessica T. Markowitz, Diana Rofail, Gerrit Vandenberg, Jessica Baldasaro, Robert J. Sanchez, Robert J. Pignolo, Richard Keen, Michelle Davis, Patrick Marquis
Publikováno v:
Advances in Therapy. 39:2796-2805
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ac8d9b86192eeb9c466ab0385c9457e
https://doi.org/10.1007/s12325-022-02096-3
https://doi.org/10.1007/s12325-022-02096-3
Autor:
Robert J. Sanchez, Siva Gummadi, Michael Robertson, Samuel F. Sears, Christian Perings, Ashley E. Burch, Michael Döring, Byron J. Colley, Christian Veltmann, Girish Shroff
Publikováno v:
Journal of Cardiovascular Nursing. 36:589-594
BACKGROUND The patient experience of heart failure involves a multi-impact symptom response with functional limitations, psychological changes, and significant treatment burden. OBJECTIVE The aim of this study was to examine the change in patient-rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400c7734578d4581ee73e79c85a1c28c
https://doi.org/10.1097/jcn.0000000000000864
https://doi.org/10.1097/jcn.0000000000000864
Publikováno v:
Cancer medicineREFERENCES.
Although cholesterol has been hypothesized to promote cancer development through several potential pathways, its role in the risk of developing hormonally driven cancer is controversial. This literature review summarizes evidence from the highest qua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7636046a8c4c32a53d06d339ed45a357
https://pubmed.ncbi.nlm.nih.gov/36444895
https://pubmed.ncbi.nlm.nih.gov/36444895
Autor:
Jessica J. Jalbert, Mohamed Hussein, Vera Mastey, Robert J. Sanchez, Degang Wang, Dana Murdock, Laura Fariñas, Jonathan Bussey, Carlos Duart, Boaz Hirshberg, David M. Weinreich, Wenhui Wei
Publikováno v:
Infectious diseases and therapy. 11(6)
Data on real-world effectiveness of subcutaneous (SC) casirivimab and imdevimab (CAS+IMD) for the treatment of coronavirus disease 2019 (COVID-19) are limited. The objective of this study was to assess the effectiveness of SC CAS+IMD versus no antibo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ece1e4ef904df2309e3958fd938076
https://pubmed.ncbi.nlm.nih.gov/36181639
https://pubmed.ncbi.nlm.nih.gov/36181639
Autor:
Jessica J. Jalbert, Mohamed Hussein, Vera Mastey, Robert J. Sanchez, Degang Wang, Dana Murdock, Laura Farinas, Jonathan Bussey, Carlos Duart, Boaz Hirshberg, David M. Weinreich, Wenhui Wei
ImportanceData on real-world effectiveness of subcutaneous (SC) administration of casirivimab and imdevimab (CAS+IMD) for treatment of COVID-19 are limited.ObjectiveTo assess effectiveness of SC CAS+IMD vs no COVID-19 antibody treatment among patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf412dff7e13b305236d229377ae5fff
https://doi.org/10.1101/2022.06.20.22276636
https://doi.org/10.1101/2022.06.20.22276636
Autor:
Dana J. Murdock, Ning Wu, Joseph S. Grimsby, Roberto A. Calle, Stephen Donahue, David J. Glass, Mark W. Sleeman, Robert J. Sanchez
Publikováno v:
Skeletal muscle. 12(1)
Background Sarcopenia is defined as age-related low muscle mass and function, and can also describe the loss of muscle mass in certain medical conditions, such as sarcopenic obesity. Sarcopenic obesity describes loss of muscle and function in obese i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05eb4909069e9e240a119c0a9d0a337a
https://pubmed.ncbi.nlm.nih.gov/36539856
https://pubmed.ncbi.nlm.nih.gov/36539856